Current Value
$120.501 Year Return
Current Value
$120.501 Year Return
Double maintains 6 strategies that include NBIX - Neurocrine Biosciences, Inc.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
FMTO | -17.91% | $45.74M | -99.96% | 0.00% |
OOMA | -14.51% | $380.34M | +82.30% | 0.00% |
EZPW | -14.31% | $753.14M | +34.74% | 0.00% |
CIG.C | -10.58% | $2.45B | +9.77% | 0.00% |
POST | -9.70% | $6.15B | +3.79% | 0.00% |
PPC | -9.63% | $11.21B | +41.54% | 0.00% |
SEG | -9.53% | $239.93M | -26.61% | 0.00% |
MVO | -9.19% | $66.70M | -38.82% | 21.64% |
LITB | -8.62% | $21.28M | -72.45% | 0.00% |
VSTA | -8.57% | $326.82M | +11.64% | 0.00% |
ESE | -7.82% | $4.69B | +67.93% | 0.18% |
BOX | -7.60% | $4.67B | +18.65% | 0.00% |
DOCS | -7.10% | $10.97B | +146.21% | 0.00% |
TRVG | -5.84% | $106.63M | +117.76% | 0.00% |
CME | -5.32% | $98.74B | +28.80% | 3.84% |
DG | -5.29% | $20.45B | -36.56% | 2.55% |
KR | -5.04% | $44.68B | +24.17% | 1.89% |
AWK | -4.79% | $27.37B | +4.54% | 2.22% |
TTWO | -4.48% | $41.01B | +59.05% | 0.00% |
VSA | -4.24% | $7.04M | -49.24% | 0.00% |
Finnhub
Neurocrine Biosciences, Inc. announced the presentation of new analyses from a Phase 4 randomized withdrawal study showing patients with tardive dyskinesia who received continued treatment with...
Yahoo
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present new data from the Phase 3 CAHtalyst™ Pediatric study showing lasting reductions in glucocorticoid doses in pediatric patients with classic congenital adrenal hyperplasia who received CRENESSITY™ (crinecerfont) for up to one year. In addition, the study showed that for patients on CRENESSITY, adrenocorticotropic hormone, 17-hydroxyprogesterone and androstenedione remained below baseline levels, despite substantially decre
Yahoo
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new analyses from a Phase 4 randomized withdrawal study (NCT03891862) showing patients with tardive dyskinesia who received continued treatment with INGREZZA® (valbenazine) capsules reported improvements across functional and health-related quality of life measures. These findings complement recently announced patient-reported outcome data from the Phase 4 KINECT-PRO™ study of INGREZZA, which was the first of its kin
Finnhub
Neurocrine Biosciences, Inc. announced it will present new data from the Phase 3 CAHtalyst?? Pediatric study showing lasting reductions in glucocorticoid doses in pediatric patients with classic...
Yahoo
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data from the Phase 3 CAHtalyst™ Adult and Pediatric studies of CRENESSITY™ (crinecerfont). The data showed that a substantial proportion of pediatric patients with classic congenital adrenal hyperplasia achieved physiologic-range glucocorticoid doses and normal androstenedione levels. Additionally, adult male patients with classic congenital adrenal hyperplasia observed improvements in select reproductive hormone levels. Both adult
Yahoo
GRFS vs. NBIX: Which Stock Is the Better Value Option?
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
TAIL | -35.12% | $140.49M | 0.59% |
VIXY | -30.99% | $109.64M | 0.85% |
BTAL | -26.59% | $361.41M | 1.43% |
IVOL | -20.37% | $353.94M | 1.02% |
FXY | -12.41% | $838.61M | 0.4% |
GBIL | -10.30% | $6.17B | 0.12% |
FTSD | -9.59% | $212.46M | 0.25% |
XHLF | -9.12% | $1.46B | 0.03% |
SPTS | -8.89% | $5.76B | 0.03% |
SCHO | -6.71% | $10.87B | 0.03% |
TBLL | -6.54% | $2.46B | 0.08% |
UTWO | -5.92% | $387.71M | 0.15% |
XONE | -5.89% | $603.24M | 0.03% |
VGSH | -5.54% | $22.38B | 0.03% |
CLIP | -5.08% | $1.50B | 0.07% |
STPZ | -4.59% | $446.46M | 0.2% |
TFLO | -4.56% | $7.06B | 0.15% |
BWX | -4.31% | $1.41B | 0.35% |
BILS | -4.17% | $3.96B | 0.1356% |
ULST | -4.02% | $637.77M | 0.2% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
FTSM | -0.16% | $6.54B | 0.45% |
SPTI | -0.19% | $8.70B | 0.03% |
BOXX | -0.25% | $6.21B | 0.19% |
FLGV | 0.31% | $976.63M | 0.09% |
JPLD | 0.34% | $1.19B | 0.24% |
WEAT | -0.34% | $115.83M | 0.28% |
BSMW | 0.49% | $102.62M | 0.18% |
IBTM | -0.55% | $313.33M | 0.07% |
SCHR | -0.57% | $10.53B | 0.03% |
TYA | 0.60% | $149.38M | 0.15% |
VTIP | -0.63% | $14.78B | 0.03% |
SHV | 0.73% | $20.94B | 0.15% |
VGIT | -0.73% | $31.33B | 0.04% |
FLMI | 0.74% | $649.76M | 0.3% |
UNG | -0.78% | $371.83M | 1.06% |
JMST | 0.79% | $3.65B | 0.18% |
SGOV | 0.86% | $45.91B | 0.09% |
OWNS | 0.88% | $134.57M | 0.3% |
SHY | 0.91% | $24.03B | 0.15% |
TDTT | 1.05% | $2.47B | 0.18% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
PBE | 47.22% | $214.12M | 0.58% |
FBT | 44.28% | $994.71M | 0.56% |
XBI | 42.35% | $4.85B | 0.35% |
FXH | 42.09% | $891.82M | 0.62% |
BBH | 42.05% | $327.42M | 0.35% |
IBB | 41.57% | $5.22B | 0.45% |
TCAF | 40.93% | $4.34B | 0.31% |
HLAL | 40.39% | $596.33M | 0.5% |
PINK | 40.28% | $131.52M | 0.5% |
QLTY | 40.05% | $1.84B | 0.5% |
CGUS | 39.86% | $5.36B | 0.33% |
KRMA | 39.82% | $603.78M | 0.43% |
IWV | 39.74% | $15.33B | 0.2% |
QQQJ | 39.70% | $610.08M | 0.15% |
FELC | 39.68% | $4.27B | 0.18% |
FTHI | 39.62% | $1.27B | 0.75% |
VTI | 39.61% | $470.88B | 0.03% |
PAUG | 39.60% | $780.66M | 0.79% |
ESGV | 39.60% | $10.14B | 0.09% |
BJUL | 39.58% | $250.71M | 0.79% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
STG | -0.03% | $27.05M | -37.35% | 0.00% |
ASPS | 0.05% | $69.98M | -57.72% | 0.00% |
RLX | -0.11% | $1.77B | -9.30% | 0.49% |
FYBR | -0.14% | $9.16B | +36.87% | 0.00% |
HTO | 0.20% | $1.76B | -13.86% | 3.19% |
NEOG | 0.22% | $1.42B | -51.08% | 0.00% |
MSIF | -0.26% | $715.25M | +28.42% | 7.05% |
HAIN | 0.31% | $162.46M | -75.84% | 0.00% |
HMST | -0.36% | $242.19M | +25.98% | 0.00% |
UNH | 0.37% | $248.87B | -47.37% | 3.06% |
CL | -0.40% | $72.64B | -5.18% | 2.25% |
FE | -0.43% | $24.49B | +5.52% | 4.06% |
LTM | 0.44% | $11.01B | -96.75% | 2.75% |
SRRK | 0.58% | $2.92B | +115.29% | 0.00% |
CHWY | -0.66% | $17.15B | +144.37% | 0.00% |
SYPR | 0.70% | $37.69M | +21.48% | 0.00% |
HSTM | -0.74% | $841.58M | +0.88% | 0.31% |
PRA | -0.74% | $1.19B | +58.17% | 0.00% |
TCMD | -0.75% | $224.35M | -29.36% | 0.00% |
EXC | -0.76% | $43.84B | +12.45% | 3.59% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
BILL | 49.56% | $4.82B | -21.32% | 0.00% |
ATR | 43.40% | $10.23B | +5.02% | 1.16% |
RRX | 38.97% | $9.27B | -12.80% | 1.00% |
GHM | 38.40% | $402.32M | +28.21% | 0.00% |
SHAK | 38.24% | $4.71B | +15.41% | 0.00% |
ARW | 37.87% | $6.26B | -7.07% | 0.00% |
CTS | 37.51% | $1.28B | -17.46% | 0.37% |
SYNA | 37.50% | $2.52B | -29.56% | 0.00% |
AXTA | 36.99% | $7.08B | -8.43% | 0.00% |
TECH | 36.95% | $7.56B | -41.77% | 0.49% |
BDC | 36.84% | $4.42B | +19.84% | 0.18% |
SLAB | 36.74% | $4.34B | +2.29% | 0.00% |
XENE | 36.41% | $2.27B | -26.70% | 0.00% |
SEE | 36.40% | $4.67B | -18.53% | 2.51% |
ZBRA | 36.29% | $15.17B | -6.72% | 0.00% |
AORT | 36.21% | $1.24B | +23.28% | 0.00% |
LITE | 35.94% | $5.40B | +66.15% | 0.00% |
BBDC | 35.66% | - | - | 11.67% |
FLEX | 35.43% | $16.07B | +43.86% | 0.00% |
NCV | 35.40% | - | - | 6.09% |